Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Business Wire - Mon Dec 22, 6:00AM CST

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s ENHERTU with the latest based on DESTINY-Breast05 Phase III trial results

AZN : 92.01 (-0.48%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology Yolowire - Mon Dec 22, 5:48AM CST

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 92.01 (-0.48%)
PPCB : 0.6430 (-2.58%)
RHHBY : 52.5300 (-0.10%)
BMY : 54.70 (-0.02%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer Business Wire - Mon Dec 15, 3:29PM CST

Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with...

AZN : 92.01 (-0.48%)
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH Business Wire - Thu Dec 4, 6:00AM CST

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers ...

AZN : 92.01 (-0.48%)
A concept image of a neon pink circuit board_ Image by Gorodenkoff via Shutterstock_
IonQ Wants to Bring Quantum Computing to Medicine. Should You Buy IONQ Stock Here? Barchart - Wed Dec 3, 9:00AM CST

With IonQ bringing quantum computing into healthcare, is now the time for investors to start paying attention to this stock?

NVDA : 190.27 (+0.88%)
AZN : 92.01 (-0.48%)
$SPX : 6,932.05 (+0.32%)
IONQ : 49.85 (+0.06%)
AMZN : 232.82 (+0.19%)
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension Business Wire - Tue Dec 2, 8:18AM CST

Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled...

AZN : 92.01 (-0.48%)
Vistagen Appoints Nick Tressler as Chief Financial Officer Business Wire - Mon Dec 1, 7:30AM CST

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

SENS : 6.05 (-2.10%)
AZN : 92.01 (-0.48%)
VTGN : 0.7201 (-1.07%)
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers Business Wire - Wed Nov 26, 6:00AM CST

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy...

AZN : 92.01 (-0.48%)
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth Business Wire - Fri Nov 21, 1:05PM CST

New capacity at AstraZeneca’s Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Fourth...

AZN : 92.01 (-0.48%)
A concept image with a brain on top of a blue circuit board_ Image by Gorodenkoff via Shutterstock_
This 1 Company Is the Nvidia of Quantum Computing. Should You Buy Its Stock Now? Barchart - Fri Nov 21, 10:23AM CST

IONQ stock is up 20% in the past 52 weeks and remains a top investment as it expands its quantum computing moat, according to investment bank J.P. Morgan.

MSFT : 487.22 (-0.16%)
NVDA : 190.27 (+0.88%)
GOOG : 316.14 (+0.15%)
GOOGL : 314.64 (+0.18%)
AZN : 92.01 (-0.48%)
IONQ : 49.85 (+0.06%)
AMZN : 232.82 (+0.19%)

Barchart Exclusives

Here’s a Smart Way to Trade Robinhood (HOOD) Stock Without Going into Lottery Mode Barchart - 5 minutes ago
While you can swing for the fences, by measuring the risk geometry of HOOD stock, you can improve your odds of success with a more realistic proposition. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot